Market Closed -
Nasdaq
21:00:00 31/05/2024 BST
5-day change
1st Jan Change
1.44
USD
-1.37%
-4.64%
+111.76%
Celsion Corporation will Change its Name to Imunon, Inc
September 21, 2022 at 05:00 am
Effective September 21, 2022, Celsion Corporation will change its name to Imunon, Inc.
Imunon, Inc. Announces CFO Changes, Effective from June 1, 2024
05-20
CI
Transcript : Imunon, Inc., Q1 2024 Earnings Call, May 13, 2024
05-13
IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
05-13
CI
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-13
CI
IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024
05-08
CI
IMUNON, Inc. Appoints Stacy R. Lindborg as President, Effective May 13, 2024
05-08
CI
Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine
04-18
MT
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
04-18
DJ
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101
04-18
CI
HC Wainwright Adjust Price Target on Imunon to $13 From $12, Keeps Buy Rating
04-01
MT
Top Midday Gainers
03-28
MT
Transcript : Imunon, Inc., Q4 2023 Earnings Call, Mar 28, 2024
03-28
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-28
CI
North American Morning Briefing : Stocks Set for -2-
03-28
DJ
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101
03-13
CI
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff
03-13
MT
Imunon, Inc. Announces Executive Changes
03-12
CI
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024
03-12
CI
Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer
12-11
CI
Transcript : Imunon, Inc., Q3 2023 Earnings Call, Nov 14, 2023
11-14
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer
11-14
CI
IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
18/10/23
CI
Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board
06/10/23
CI
Transcript : Imunon, Inc. - Special Call
14/09/23
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
More about the company
Last Close Price
1.44
USD
Average target price
10
USD
Spread / Average Target
+594.44%
Consensus
1st Jan change
Capi.
+111.76% 13.54M +11.91% 118B +11.60% 106B -4.68% 24.28B -0.82% 21.96B -10.12% 18.16B -42.12% 16.37B -17.47% 15.56B +2.77% 13.63B +34.58% 12.27B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
IMUNON, INC. 
